News | September 16, 2025
Advent to sell generic drugmaker Zentiva to GTCR
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
With close to 2,800 highly skilled employees, GITC is now one of the largest technology centres across the Life Sciences industry in the country
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Subscribe To Our Newsletter & Stay Updated
